Open access · US-GOV via ClinicalTrials.gov Clinical trial

The Bioavailability of Compounded and Generic Rapamycin in Normative Aging Individuals: A Retrospective Study and Review With Clinical Implications

Authors not listed

AgelessRx · 2023

Epigenetic alterations Rapamycin / mTOR inhibition Human Randomized controlled trial Review

Abstract

This study collected real-world evidence to better understand and define the relative bioavailability ratio between compounded mTOR-inhibiting drug studied for extending healthspan and lifespan." style="text-decoration:underline dotted; text-underline-offset:2px; cursor:help;">rapamycin and generic rapamycin, with a specific focus on relative efficacy in increasing rapamycin levels in the blood (blood rapamycin levels).

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source: ClinicalTrials.gov
Canonical: link ↗
Fetched: 2026-10-13 MST

Cite this

APA

Anonymous. (2023). The Bioavailability of Compounded and Generic Rapamycin in Normative Aging Individuals: A Retrospective Study and Review With Clinical Implications. <em>AgelessRx</em>. https://clinicaltrials.gov/study/NCT06550271

Vancouver

Anonymous. The Bioavailability of Compounded and Generic Rapamycin in Normative Aging Individuals: A Retrospective Study and Review With Clinical Implications. AgelessRx. 2023.

BibTeX

@misc{anon2023TheBio, title = {The Bioavailability of Compounded and Generic Rapamycin in Normative Aging Individuals: A Retrospective Study and Review With Clinical Implications}, author = {Anonymous}, journal = {AgelessRx}, year = {2023}, }